AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00765128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study NCT01827345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
Study NCT03653052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
Study NCT01598519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: suicide intervention
Description: universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net.
Study NCT02543437 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trident Acetabular X3 Insert
Study NCT00059787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00059787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00059787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Given PO
Study NCT00472797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation Non Titrated
Description: human interferon beta 1a - Rebif New Formulation
Study NCT00472797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation Titrated
Description: Human interferon beta 1a Rebif New Formulation
Study NCT04300829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cicaderma + simple hygiene rules
Description: Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
Study NCT04300829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple hygiene rules and a maximum of one topical treatment
Description: Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
Study NCT02547402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
Study NCT02547402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: It is statin medicine used to lower cholesterol and triglycerides in the blood.
Study NCT02547402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin® (combination of simvastatin and ezetimibe)
Description: It lowers bad cholesterol in the blood, and raises good cholesterol
Study NCT03165955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
Study NCT01805726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xylocain
Description: Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
Study NCT01805726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: (A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
Study NCT00174382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
Study NCT04050969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
Study NCT04050969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation (AF) Catheter Ablation
Description: Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
Study NCT04050969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AF) Catheter Ablation
Description: Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
Study NCT06716723 — intervention group
Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: Receipt of a laparoscopic nephrectomy for kidney donation
Study NCT03470870 — intervention group
Intervention type: OTHER
Intervention: Comparative analysis of the characteristics
Description: * Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ChiRunning training
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChiRunning training
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: unblinded accelerometer
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: participation in online social network
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: participation in study website
Study NCT02059382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology support for behavior change
Study NCT01736514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: oral
Study NCT01736514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: oral
Study NCT01493778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
Study NCT02102841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Study NCT02102841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin suction blister
Study NCT02102841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mantoux test
Study NCT01611246 — intervention group
Intervention type: DEVICE
Intervention: Iontophoresis System With Earset
Description: iontophoresis of lidocaine-based solution for numbing tympanic membrane
Study NCT02538107 — intervention group
Intervention type: DRUG
Intervention: Methoxy-polyethyleneglycol epoetin beta
Study NCT00546754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
Study NCT00546754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Valsartan (+) Hydrochlorothiazide
Description: Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
Study NCT00125645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan Oral Tablet
Study NCT01993160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorocholine (18F-FCH) Injection
Description: Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
Study NCT01993160 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan
Description: A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
Study NCT01993160 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole body MRI
Description: A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: single pilot interview
Description: Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals-of-care (GOC) video
Description: Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals-of-care (GOC) video and narrative question
Description: subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part 2
Description: Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
Study NCT01912131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2
Description: Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
Study NCT05600335 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
Study NCT00895531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depodur
Description: 7.5 mg Depodur via the epidural catheter
Study NCT00895531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
Study NCT03375151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG based feedback
Description: Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
Study NCT03375151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard practice based feedback
Description: Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
Study NCT03375151 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard practice based feedback
Description: Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
Study NCT03375151 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No feedback
Description: Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
Study NCT02650544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
Study NCT02650544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
Study NCT01833923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: oral medicine.
Study NCT03467386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT
Study NCT03467386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03467386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administer according to City of Hope standard operating procedures
Study NCT03467386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03467386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03467386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03467386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given CIV
Study NCT03467386 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Undergo TMLI
Study NCT01781585 — intervention group
Intervention type: PROCEDURE
Intervention: hemodialysis
Description: Patients were randomized to receive CVVH or SLED and the next day on the other.
Study NCT04456725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive management
Description: The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
Study NCT04456725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual care
Study NCT04186468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic
Description: The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
Study NCT00709358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of microbial DNA in blood by SeptiFast®
Description: The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours.
Study NCT00709358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: detection of microbial DNA in blood by blood culture
Description: A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
Study NCT01839526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
Study NCT03632759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Participants will receive subcutaneous (SC) liraglutide for 8 weeks
Study NCT03632759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous (SC) golimumab for 8 weeks
Study NCT05855291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
Study NCT03840122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACB + IPACK block with injection of local anesthetic
Description: ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml
Study NCT03840122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACB + IPACK block without injection
Description: ACB + IPACK block without an injection of local anesthetic
Study NCT01805726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: (D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
Study NCT03875937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic 1 gram
Description: To be administered intramuscularly (2 injections)
Study NCT03045237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercises classes
Description: 3 physical exercises classes, one of them in the pool.
Study NCT00701974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase (IRUXOL)
Description: patients will be treated with collagenase one time per day.
Study NCT00701974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase (Kollagenase)
Description: patients will be treated with collagenase one time per day.
Study NCT05495113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YMS-201B (Device: Mind STIM)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT05495113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation using YMS-201B
Description: Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02009748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: oral administration of colecalciferol 2.800 IU once daily
Study NCT02009748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo (vehicle) once daily
Study NCT04322149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Study NCT04470375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Pain Neuroscience Education
Description: Use of virtual reality media to provide pain neuroscience education
Study NCT02359695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
Study NCT01021813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Oral tablet (30 mg and 10 mg), administered daily before bedtime
Study NCT01021813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-matched Placebo to Suvorexant
Description: Oral tablet, administered daily before bedtime